Analysts Set Monopar Therapeutics Inc. (NASDAQ:MNPR) Target Price at $56.50

Monopar Therapeutics Inc. (NASDAQ:MNPR - Get Free Report) has received an average recommendation of "Moderate Buy" from the five research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold recommendation and four have given a buy recommendation to the company. The average 1 year price objective among analysts that have issued ratings on the stock in the last year is $56.50.

MNPR has been the subject of several recent analyst reports. HC Wainwright restated a "buy" rating and set a $40.00 target price on shares of Monopar Therapeutics in a research note on Tuesday, April 1st. Jones Trading restated a "hold" rating on shares of Monopar Therapeutics in a research note on Wednesday, April 2nd. Piper Sandler restated an "overweight" rating and set a $76.00 price objective on shares of Monopar Therapeutics in a report on Wednesday, March 19th. Wall Street Zen upgraded Monopar Therapeutics from a "sell" rating to a "hold" rating in a research note on Thursday, May 22nd. Finally, Chardan Capital started coverage on shares of Monopar Therapeutics in a report on Monday. They issued a "buy" rating and a $60.00 price target on the stock.

Insider Activity

In other news, major shareholder Tactic Pharma Llc sold 33,334 shares of Monopar Therapeutics stock in a transaction dated Wednesday, April 2nd. The shares were sold at an average price of $35.00, for a total value of $1,166,690.00. Following the completion of the transaction, the insider now directly owns 822,255 shares of the company's stock, valued at approximately $28,778,925. The trade was a 3.90% decrease in their position. The transaction was disclosed in a filing with the SEC, which is accessible through this hyperlink. Company insiders own 20.50% of the company's stock.

Hedge Funds Weigh In On Monopar Therapeutics

A number of large investors have recently bought and sold shares of the business. AlphaQuest LLC acquired a new stake in shares of Monopar Therapeutics during the 1st quarter worth approximately $44,000. JPMorgan Chase & Co. bought a new position in Monopar Therapeutics during the 4th quarter worth $45,000. Gerber LLC acquired a new stake in Monopar Therapeutics in the first quarter worth $204,000. OMERS ADMINISTRATION Corp bought a new stake in Monopar Therapeutics in the first quarter valued at $328,000. Finally, Jane Street Group LLC acquired a new position in shares of Monopar Therapeutics during the first quarter valued at $377,000. Institutional investors own 1.83% of the company's stock.

Monopar Therapeutics Trading Up 9.7%

NASDAQ:MNPR traded up $3.09 during trading hours on Monday, hitting $35.01. The stock had a trading volume of 24,388 shares, compared to its average volume of 358,088. The company has a market cap of $214.26 million, a PE ratio of -10.06 and a beta of 0.99. The business has a 50 day simple moving average of $36.96 and a two-hundred day simple moving average of $34.60. Monopar Therapeutics has a 1-year low of $1.72 and a 1-year high of $54.30.

Monopar Therapeutics (NASDAQ:MNPR - Get Free Report) last released its quarterly earnings results on Tuesday, May 13th. The company reported ($0.38) earnings per share for the quarter, beating analysts' consensus estimates of ($0.65) by $0.27. Research analysts expect that Monopar Therapeutics will post -1.65 EPS for the current fiscal year.

Monopar Therapeutics Company Profile

Monopar Therapeutics Inc, a clinical-stage biopharmaceutical company, engages in developing therapeutics for the treatment of cancer in the United States. Its lead product candidate in development is Validive, a clonidine hydrochloride mucobuccal tablet that is in Phase 2b/3 clinical trial for the prevention of chemoradiotherapy induced severe oral mucositis in patients with oropharyngeal cancer.